Compare HTZ & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTZ | NGNE |
|---|---|---|
| Founded | 1918 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 809.1M | 744.9M |
| IPO Year | 2021 | 2014 |
| Metric | HTZ | NGNE |
|---|---|---|
| Price | $1.79 | $33.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $5.67 | ★ $63.57 |
| AVG Volume (30 Days) | ★ 12.9M | 234.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.98 | 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,504,000,000.00 | N/A |
| Revenue This Year | $4.94 | N/A |
| Revenue Next Year | $3.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.45 | $15.93 |
| 52 Week High | $8.18 | $43.66 |
| Indicator | HTZ | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 41.25 |
| Support Level | N/A | $31.20 |
| Resistance Level | N/A | $33.99 |
| Average True Range (ATR) | 0.00 | 1.95 |
| MACD | 0.00 | -0.47 |
| Stochastic Oscillator | 0.00 | 20.29 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through its Hertz, Dollar and Thrifty brands. The company has two reportable segments: i) Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean, ii) International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The company maintains a substantial network of company-operated rental locations, a majority of which are in Europe, and has franchisees and partners that operate rental locations under brands. Geographical markets include North America, Europe, Pacific Asia, Middle East and Africa, and Latin America.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.